Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2026-01-10 @ 5:30 PM
Study NCT ID:
NCT06725758
Status:
RECRUITING
Last Update Posted:
2024-12-10
First Post:
2024-11-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours
Sponsor:
Orion Corporation, Orion Pharma
Organization:
Study Overview
Official Title:
Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours
Status:
RECRUITING
Status Verified Date:
2024-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEADES
Brief Summary:
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: